Nanotechnology-based PD-L1 siRNA codelivery systems for improving cancer immunotherapy
{{output}}
Immune checkpoint blockade targeting the PD-1/PD-L1 (Programmed cell death protein 1/Programmed death-ligand 1) axis has transformed cancer therapy. However, antibodies non-specifically bind to PD-1 or PD-L1 on both malignant and normal cells, resulting in imm... ...
